Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.48 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | CCNK | O75909 | 2/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540867 | 1.00 | ALK (0.62) | ALKAURKBAURKAINCENPTPX2 | |
| Trifluoroacetic Acid SCHEMBL4088053 | 0.92 | ALK (0.55) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL99234 | 0.82 | GRM4 (0.65) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL30009527 | 0.82 | GRM4 (0.65) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL100912 | 0.80 | GRM4 (0.52) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL29540625 | 0.80 | ALK (0.61) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL29540647 | 0.80 | ALK (0.61) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL101922 | 0.80 | ALK (0.61) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL29541281 | 0.80 | GRM4 (0.52) | ALKAURKBAURKAINCENPTPX2 | |
| SCHEMBL99415 | 0.80 | ALK (0.61) | ALKAURKBAURKAINCENPTPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348023-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | claimed |
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | claimed |
| EP-2343299-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-11-04 | — | — | EP | claimed |
| EP-2348023-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-05-06 | — | — | EP | claimed |
| CN-103254190-A | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORP | 2013-08-21 | — | — | CN | claimed |
| CN-103214483-A | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORP | 2013-07-24 | — | — | CN | claimed |
| CN-103214484-A | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORP A DELAWARE CORP | 2013-07-24 | — | — | CN | claimed |
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | claimed |
| EP-2474545-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-07-11 | — | — | EP | claimed |
| EP-2455382-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2426129-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-03-07 | — | — | EP | claimed |
| EP-1966202-B1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2011-09-21 | — | — | EP | claimed |
| EP-2348023-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-27 | — | — | EP | claimed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | claimed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | claimed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | claimed |
| CN-101448826-A | Heteroaryl substituted pyrrolo [2 ] as janus kinase inhibitors | INCYTE CORP (US) | 2009-06-03 | — | — | CN | claimed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | claimed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALK 458/4885AURKB 198/4885AURKA 485/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | ALK 643/4885AURKB 613/4885AURKA 594/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALK 458/4885AURKB 198/4885AURKA 485/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALK 458/4885AURKB 198/4885AURKA 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.